Isotretinoin: Dose, duration and relapse. What does 30 years of usage tell us?

Australasian Journal of Dermatology

Volumn 54, Issue 3, 2013, Pages 157-162

  Rademaker, Marius ^a  

^a WAIKATO HOSPITAL   (New Zealand)

Author keywords

acne vulgaris; adverse effects; dose; isotretinoin; relapse; retinoid

Indexed keywords

ISOTRETINOIN;

ACNE VULGARIS; APOPTOSIS; CANCER CELL; CELL DIFFERENTIATION; CELL GROWTH; GENE EXPRESSION; HUMAN; MORPHOGENESIS; PATHOPHYSIOLOGY; PROMOTER REGION; PROSPECTIVE STUDY; RELAPSE; REVIEW; SEBACEOUS GLAND; SMOKING; TERATOGENICITY; WOUND HEALING;

ACNE VULGARIS; ADVERSE EFFECTS; DOSE; ISOTRETINOIN; RELAPSE; RETINOID;

ACNE VULGARIS; AGE FACTORS; DERMATOLOGIC AGENTS; HUMANS; ISOTRETINOIN; RECURRENCE; SMOKING;

EID: 84881311594     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/j.1440-0960.2012.00947.x     Document Type: Review

References (48)

1. Layton AM, Cunliffe WJ,. Guidelines for optimal use of isotretinoin in acne. J. Am. Acad. Dermatol. 1992; 27: S2-7.
2. Peck GL, Olsen TG, Yoder FW, et al. Prolonged remissions of cystic and conglobata acne with 13-cis-retinoic acid. N. Engl. J. Med. 1979; 300: 329-333.
3. Farrell LN, Strauss JS, Stranieri AM,. The treatment of severe cystic acne with 13-cis-retinoic acid. Evaluation of sebum production and the clinical response in a multiple-dose trial. J. Am. Acad. Dermatol. 1980; 3: 602-611.
4. Plewig G, Gollnick H, Meigel W, et al. 13-cis retinoic acid in the oral therapy of acne conglobata. Results of a multi-center study. Hautarzt 1981; 32: 634-646.
5. Strauss JS, Stranieri AM,. Changes in long-term sebum production from isotretinoin therapy. J. Am. Acad. Dermatol. 1982; 6: 751-756.
6. Peck GL, Olsen TG, Butkus D, et al. Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study. J. Am. Acad. Dermatol. 1982; 6: 735-745.
7. Jones DH, King K, Miller AJ, et al. A dose-response study of I3-cis-retinoic acid in acne vulgaris. Br. J. Dermatol. 1983; 108: 333-343.
8. Marsden JR, Laker MF, Ford GP, et al. Effect of low dose cyproterone acetate on the response of acne to isotretinoin. Br. J. Dermatol. 1984; 110: 697-702.
9. Jones DH, Cunliffe WJ,. Remission rates in acne patients treated with various doses of 13-cis-retinoic acid (isotretinoin). Br. J. Dermatol. 1984; 111: 123-125.
10. Harms M, Duvanel T, Williamson C, et al. Isotretinoin for acne: should we consider the total cumulative dose. In:, Marks R, Plewig G, (eds). Acne and Related Disorders. London: Martin Dunitz, 1989; 203-206.
11. Cunliffe WJ, van de Kerkhof PCM, Caputo R, et al. Roaccutane treatment guidelines: results of an international survey. Dermatology 1997; 194: 351-357.
12. Kim J, Ochoa MT, Krutzik SR, et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J. Immunol. 2002; 169: 1535-1541.
13. Chronnell CM, Ghali LR, Ali RS, et al. Human beta defensin-1 and -2 expression in human pilosebaceous units: upregulation in acne vulgaris lesions. J. Invest. Dermatol. 2001; 117: 1120-1125.
14. Kuenzli S, Saurat J-H,. Retinoids. In:, Bolognia JL, Jorizzo JL, Rapini RP, (eds). Dermatology, 2nd edn. Elsevier, 2008. Available from URL: http://www.expertconsult.com. (Accessed April 2012).
15. Layton A,. The use of isotretinoin in acne. Dermatoendocrinology 2009; 1: 162-169.
16. Nelson AM, Zhao W, Gilliland KL, et al. Isotretinoin temporally regulates distinct sets of genes in patient skin. J. Invest. Dermatol. 2009; 129: 1038-1042.
17. Nelson AM, Zhao W, Gilliland KL, et al. Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinology 2009; 1: 177-187.
18. Rademaker M,. Adverse effects of isotretinoin. A retrospective study of 1743 patients. Australas. J. Dermatol. 2010; 51: 248-253.
19. Strauss JS, Rapini RP, Shalita AR, et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J. Am. Acad. Dermatol. 1984; 10: 490-496.
20. Plewig G, Dressel H, Pfleger M, et al. Low dose isotretinoin combined with tretinoin is effective to correct abnormalities of acne. J. Dtsch Dermatol. Ges. 2004; 2: 31-45.
21. Geissler SE, Michelsen S, Plewig G,. Very low dose isotretinoin is effective in controlling seborrhea. J. Dtsch Dermatol. Ges. 2003; 1: 952-958.
22. Rademaker M, Wishart J, Birchall N,. Isotretinoin 5 mg daily for persistent low-grade adult acne vulgaris-a randomised double blind study. (in-press: abstract EADV Prague 2012).
23. Chivot M,. Acne flares and deteriorations during oral isotretinoin therapy. Ann. Dermatol. Venereol. 2001; 128: 224-228.
24. Borghi A, Mantovani L, Minghetti S, et al. Acute acne flare following isotretinoin administration: potential protective role of low starting dose. Dermatology 2009; 218: 178-180.
25. Chivot M, Midoun H,. Isotretinoin and acne-a study of relapses. Dermatologica 1990; 180: 240-243.
26. Lehucher-Ceyrac D, Weber-Buisset MJ,. Isotretinoin and acne in practice: a prospective analysis of 188 cases over 9 years. Dermatology 1993; 186: 123-128.
27. Quereux G, Volteau C, N'Guyen JM, et al. Prospective study of risk factors of relapse after treatment of acne with oral isotretinoin. Dermatology 2006; 212: 168-176.
28. Shahidullah M, Tham SN, Goh CL,. Isotretinoin therapy in acne vulgaris: a 10-year retrospective study in Singapore. Int. J. Dermatol. 1994; 33: 60-63.
29. Stainforth JM, Layton AM, Taylor JP, et al. Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course? Br. J. Dermatol. 1993; 129: 297-301.
30. Zouboulis CC,. The truth behind this undeniable efficacy-recurrence rates and relapse risk factors of acne treatment with oral isotretinoin. Dermatology 2006; 212: 99-100.
31. Bottomley WW, Cunliffe WJ,. Severe flares of acne following isotretinoin: large closed comedones (macrocomedones) are a risk factor. Acta Derm. Venereol. 1993; 73: 74.
32. Goulden V, Clark SM, McGeown C, et al. Treatment of acne with intermittent isotretinoin. Br. J. Dermatol. 1997; 137: 106-108.
33. Harms M, Masouye I, Radeff B,. The relapses of cystic acne after isotretinoin treatment are age-related: a long-term follow-up study. Dermatologica 1986; 172: 148-153.
34. Lehucher-Ceyrac D, de La SP, Chastang C, et al. Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients. Dermatology 1999; 198: 278-283.
35. Gollnick HP, Finlay AY, Shear N,. Global alliance to improve outcomes in acne. Can we define acne as a chronic disease? If so, how and when? Am. J. Clin. Dermatol. 2008; 9: 279-284.
36. Thiboutot DM, Lookingbill DP,. Acne: acute or chronic disease? J. Am. Acad. Dermatol. 1995; 32 (5 Pt 3): S2-5.
37. Perkins AC, Maglione J, Hillebrand GG, et al. Acne vulgaris in women: prevalence across the life span. J. Womens Health (Larchmt) 2012; 21: 223-230.
38. Poli F, Dreno B, Verschoore M,. An epidemiological study of acne in female adults: results of a survey conducted in France. J. Eur. Acad. Dermatol. Venereol. 2001; 15: 541-545.
39. Seukeran DC, Cunliffe WJ,. Acne vulgaris in the elderly: the response to low-dose isotretinoin. Br. J. Dermatol. 1998; 139: 99-101.
40. Palmer RA, Sidhu S, Goodwin PG,. 'Microdose' isotretinoin. Br. J. Dermatol. 2000; 143: 205-206.
41. Williams C, Layton AM,. Persistent acne in women: implications for the patient and for therapy. Am. J. Clin. Dermatol. 2006; 7: 281-290.
42. Thielitz A, Krautheim A, Gollnick H,. Update in retinoid therapy of acne. Dermatol. Ther. 2006; 19: 272-279.
43. Fritsch P,. Use of systemic retinoids in dermatology. Wien. Klin. Wochenschr. 1983; 95: 817-822.
44. Bagatin E,. Oral isotretinoin: the most promising dermatological off-label uses. Expert Rev. Dermatol. 2010; 5: 617-626.
45. Hernandez-Perez E, Khawaja HA, Alvarez TY,. Oral isotretinoin as part of the treatment of cutaneous aging. Dermatol. Surg. 2000; 26: 649-652.
46. Kalil CL, Fachinello FZ, Lamb FM, et al. Use of oral isotretinoin in photoaging therapy. Skinmed 2008; 7: 10-14.
47. Rabello-Fonseca RM, Azulay DR, Luiz RR, et al. Oral isotretinoin in photoaging: clinical and histopathological evidence of efficacy of an off-label indication. J. Eur. Acad. Dermatol. Venereol. 2009; 23: 115-123.
48. Bagatin E, Parada MO, Miot HA, et al. A randomized and controlled trial about the use of oral isotretinoin for photoaging. Int. J. Dermatol. 2010; 49: 207-214.